Result for
Tag: vaccine
May 17, 2021
Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel — 33 U.S. Sites, January–March 2021
Among US healthcare personnel, one dose of either the Pfizer-BioNTech or Moderna vaccines was 82% effective against symptomatic COVID-19, and 2 doses were 94% effective. Interim results from a test-negative case-control study conducted in 25 states and enrolling 623 case-patients and 1,220 controls as of March 18, 2021 indicate that vaccine effectiveness is similar to…
Durability of MRNA-1273-Induced Antibodies against SARS-CoV-2 Variants
[Pre-print, not peer-reviewed] An analysis of sera from participants in the Moderna vaccine trial (n=24) found that most individuals maintained both binding and functional antibodies against the B.1.1.7, B.1.351, P.1, B.1.429, and B.1.526 SARs-CoV-2 variants for 6 months, although at lower levels relative to wildtype and D614G. The B.1.1.7 lineage had little impact on antibody…
Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca Vaccines on Covid-19 Related Symptoms, Hospital Admissions, and Mortality in Older Adults in England: Test Negative Case-Control Study
A case-control study of the effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines among adults aged 70 and older (n = 156,930) found that one dose of either vaccine was about 80% effective at preventing hospital admission with COVID-19, and a single dose of Pfizer-BioNTech was 85% effective at preventing death (follow-up was insufficient to assess…
May 14, 2021
Short-Term Antibody Response Afer 1 Dose of BNT162b2 Vaccine in Patients Receiving Hemodialysis
A study of persons receiving onsite hemodialysis and health care worker controls (N=210) found that a single dose of the Pfizer-BioNTech vaccine failed to elicit detectable IgG antibodies in 57% of hemodialysis patients and 5% of health care workers without previous SARS-CoV-2 infection at 4 weeks following vaccination. Among hemodialysis patients with previous SARS-CoV-2 infection,…
BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants
An in vitro study of serum neutralization after two doses of Pfizer-BioNTech vaccine found that variants B.1.526, B.1.429, and B.1.1.7+E484K remained susceptible to vaccine-elicited neutralizing antibodies at a level equivalent to the neutralization of wild-type USA-WA1/2020 strain. The authors suggest that these results indicate the additional E484K mutation, also found in the B.1.351 and B.1.526…
Immunogenicity of COVID-19 MRNA Vaccines in Pregnant and Lactating Women
A small (N=46) study of pregnant and lactating persons found that mRNA vaccines produced binding, neutralizing, and functional non-neutralizing antibody responses as well as CD4 and CD8 T-cell responses. Additionally, binding and neutralizing antibodies were also detectable in cord blood, suggesting placental transfer of maternal antibodies and conferral of immunity to infants. Post-vaccination in vitro…
Antibody Responses to Single-Dose SARS-CoV-2 Vaccination in Patients Receiving Immunomodulators for Immune-Mediated Inflammatory Disease
A study of persons with immune-mediated inflammatory diseases (IMID) (N=120) found that 15% failed to produce detectable SARS-CoV-2 antibodies 23-46 days after one dose of the Pfizer-BioNTech or Astra-Zeneca vaccines. In contrast, nearly 100% of persons without IMID who receive one dose of either vaccine have been shown to produce antibodies within this time frame….
May 13, 2021
mRNA Vaccine-Induced SARS-CoV-2-Specific T Cells Recognize B.1.1.7 and B.1.351 Variants but Differ in Longevity and Homing Properties Depending on Prior Infection Status
[Pre-print, not peer-reviewed] CD4+ T cell responses elicited by COVID-19 mRNA vaccines respond similarly to spike protein epitopes derived from the SARS-CoV-2 B.1.1.7 and B.1.351 variants of concern and the ancestral strain, based on an analysis of 24 specimens obtained at 3 different timepoints from 8 fully vaccinated individuals. The second vaccine dose appeared to…
May 11, 2021
Cerebral Venous Thrombosis and Portal Vein Thrombosis a Retrospective Cohort Study of 537913 COVID-19 Cases
[Pre-print, not peer-reviewed] Risk of diagnosis for cerebral venous thrombosis (CVT) and portal vein thrombosis (PVT) within 2 weeks of a COVID-19 diagnosis was 6.6-fold higher and 7.4-fold higher, respectively, compared to receiving a COVID-19 mRNA vaccine according to a retrospective study of administrative data in the US. Researchers compared patients with a COVID-19 diagnosis…
May 10, 2021
Short-Term Effects of BNT162b2 MRNA COVID-19 Vaccination on Physiological Measures a Prospective Study
[Pre-print, not peer-reviewed] A prospective study of adults (n = 160) in Israel who had not been previously infected with SARS-CoV-2 evaluated physiological changes in participants before and after their second Pfizer-BioNTech dose. Participants were given a chest-patch sensor to wear for four days, starting one day before vaccination. The sensor measured 13 physiological parameters…
Previous page Next page